How should biosimilars be used to treat rheumatic diseases?

(Wiley) Products that are 'biosimilar' or interchangeable with a licensed biological product hold considerable promise for the treatment of a variety of medical conditions such as rheumatic diseases, and possibly at a reduced cost. In Arthritis& Rheumatology, the American College of Rheumatology (ACR) has published its latest position statement (or Whitepaper) on the rationale for the use of biosimilars in clinical practice.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news